Glutamatergic hyperactivity in the nucleus striatum, the main basal ganglia input, has been
involved in the progression of Parkinson's disease (PD) and the onset of L-Dopa-induced …

Levodopa remains the primary drug for controlling motor symptoms in Parkinson's disease
through the whole course, but over time, complications develop in the form of dyskinesias …

Dopamine loss in Parkinson's disease (PD) is associated with abnormal oscillatory activity in
the cortico-basal ganglia network. However, the oscillatory pattern of striatal neurons in PD …

Long-term dopamine (DA) replacement therapy in Parkinson's disease (PD) leads to the
development of abnormal involuntary movements known as l-Dopa–induced dyskinesia …

For more than three decades it has been known, that striatal neurons become hyperactive
after the loss of dopamine input, but the involvement of dopamine (DA) D1‐or D2‐receptor …

Abstract L-DOPA-induced dyskinesia (LID) is a major complication of long-term dopamine
replacement therapy in Parkinson's disease. Characteristic neural oscillation and abnormal …

ABSTRACT N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors
that mediate a slow, Ca 2+-permeable component of excitatory neurotransmission …

Background Parkinson's disease patients on chronic levodopa often suffer from motor
complications, which tend to reduce their quality of life. Levodopa-induced dyskinesia (LID) …

Hyperexcitability in the corticostriatal glutamatergic pathway may have a pivotal role in the
pathogenesis of Parkinson's disease (PD). Metabotropic glutamate receptors (mGluRs) …

A large body of work during the past several decades has been focused on therapeutic
strategies to control L-DOPA-induced dyskinesias (LIDs), common motor complications of …